Lilly Announces Dr. Lechleiter's Return

                   Lilly Announces Dr. Lechleiter's Return

PR Newswire

INDIANAPOLIS, July 8, 2013

INDIANAPOLIS, July 8, 2013 /PRNewswire/ --Eli Lilly and Company (NYSE:LLY)
today announced that John C. Lechleiter, Ph.D., has returned to his duties as
chairman, president, and chief executive officer. Lechleiter has been on
medical leave since his scheduled surgery for a dilated aorta on May 13,
2013.Lechleiter's surgery and recovery were successful and he has been
cleared by his personal physician and the company's employee health services
physician to return to full-time work.

"I am overwhelmed and humbled by the tremendous support and well-wishes I have
received from my friends and fellow Lilly colleagues around the world,"
Lechleiter said. "I return to Lilly with renewed energy and enthusiasm, along
with a new perspective on health and wellness and the critical importance of
new medicines in advancing patient care.

"I want to thank and acknowledge Derica Rice for the important role he played
during my absence, as well as Ellen Marram for her leadership of the Lilly
board," added Lechleiter.

Derica W. Rice will continue in his role as executive vice president, global
services and chief financial officer. Rice had assumed the additional role of
acting chief executive officer during Lechleiter's medical leave. Ellen R.
Marram will continue in her role as the board's lead independent director
after serving as acting chairperson of the board of directors during
Lechleiter's medical leave.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers-
through medicines and information- for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com. C-LLY

Refer to: (317) 433-9899 – Edward Sagebiel; egs@lilly.com
 (317) 276-5795 – Mark Taylor; taylor_mark_e@lilly.com

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Website: http://www.lilly.com
 
Press spacebar to pause and continue. Press esc to stop.